Agenus (NASDAQ:AGEN) Shares Cross Above 200-Day Moving Average – What’s Next?

Agenus Inc. (NASDAQ:AGEN) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.43 and traded as high as $3.43. Agenus shares last traded at $3.41, with a volume of 659,577 shares changing hands.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Weiss Ratings restated a “sell (d)” rating on shares of Agenus in a research report on Tuesday, June 16th. Zacks Research downgraded Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Wall Street Zen upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $23.00.

Agenus Stock Performance

The company has a market cap of $141.99 million, a PE ratio of 2.14 and a beta of 1.55. The company’s 50-day simple moving average is $3.38 and its 200 day simple moving average is $3.43.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 EPS for the quarter, missing the consensus estimate of $2.10 by ($1.08). Agenus had a negative return on equity of 31.66% and a net margin of 50.49%.The business had revenue of $33.74 million during the quarter, compared to analyst estimates of $129.50 million. Analysts forecast that Agenus Inc. will post 0.02 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AGEN. Renaissance Technologies LLC grew its stake in Agenus by 721.1% during the 4th quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock worth $1,707,000 after purchasing an additional 477,346 shares in the last quarter. Marshall Wace LLP acquired a new stake in Agenus in the 2nd quarter valued at about $1,976,000. AQR Capital Management LLC raised its position in Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after purchasing an additional 427,604 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Agenus by 110.0% in the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after buying an additional 220,327 shares during the period. Finally, Raymond James Financial Inc. grew its position in shares of Agenus by 16,654.0% during the third quarter. Raymond James Financial Inc. now owns 145,760 shares of the biotechnology company’s stock worth $561,000 after buying an additional 144,890 shares in the last quarter. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.